Darya-Varia Laboratoria Implements Business Diversification Strategy

Financial Highlights for 2025

PT Darya-Varia Laboratoria Tbk (DVLA) is strengthening its performance heading into 2026 through a comprehensive business diversification strategy. The company's financial results for the first nine months of 2025 show significant progress, with revenue reaching Rp 1.62 trillion, representing a 2.2% year-on-year (YoY) increase. More impressively, net profit surged 11.5% YoY to Rp 164.3 billion, demonstrating the effectiveness of their strategic initiatives.

Diversification Strategy

Ian Martin Wibawa Kloer, President Director of Darya-Varia Laboratoria, explained that despite facing economic challenges in early 2025, the company's diverse product portfolio has been a key factor in its business resilience. The company maintains a broad range of products including prescription drugs, over-the-counter medicines, and consumer goods. This diversification strategy has proven particularly effective, with the consumer or personal care segment emerging as a major contributor to sales performance.

Segment Performance

The consumer/personal care segment was identified as the main contributor to sales achievements throughout the year, accounting for approximately 15% of total sales. This performance underscores the success of DVLA's diversification efforts beyond traditional pharmaceutical products. The company's ability to maintain growth across multiple product categories has positioned it well for future challenges.

Market Outlook

As DVLA enters 2026, the company is well-positioned to continue its growth trajectory. The diversification strategy, coupled with its strong financial performance in 2025, provides a solid foundation for future expansion. The company's balanced portfolio across different healthcare segments is likely to continue driving its success in the Indonesian market.